[1] Teniente VR, Solorio S, Vargas SE, et al.Improvement of diastolic function after regression of left ventricular hypertrophy[J]. Arch Cardiol Mex, 2008, 78(4):392-399. [2] Okin PM, Kjeldsen SE, Julius S, et al.All-cause and cardiovascular mortalityin relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy[J]. Eur Heart J, 2010, 31(18):2271-2279. [3] Ueshima K, Yasuno S, Oba K, et al.Effects of cardiac complicationson cardiovascular events in Japanese high-risk hypertensive patients:subanalysis of the CASE-J trial[J]. Cire J, 2009, 73(6):1080-1085. [4] Verdecchia P, Angeli F, Achilli P, et al.Echocardiographic left ventricularhypertrophy in hypertension:marker for future events or mediator of events[J]. Curr Opin Cardiol, 2007, 22(4):329-334. [5] Cohn JN, Yellin AM. Learned precise cardiovascular control through graded central sympathetic stimulation[J]. J Hypertens Suppl, 1984, 2(3):77-79. [6] Jobe LJ, Melendez GC, Levick SP, et al.TNF-alpha inhibition attenuates adverse myocardial remodeling in a rat model of volume overload[J]. Am J PhysiolHeart Circ Physiol, 2009, 297(4):1462-1468. [7] Taniguehi T, Kurita A, Kobayashi K, et al.Dose and time related effects of dexmedetomidine on mortality and inflammatory responses to endotoxin-induced shock in rats[J]. J Anesth, 2008, 22(3):221-228. [8] Lang RM, Bierig M, Devereux RB, et al.Recommendations for chamber quantification:a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology[J]. J Am Soc Echocardiogr, 2005, 18(12):1440-1463. [9] Diez J. Towards a new paradigm about hypertensive heart disease[J]. Med Clin North Am, 2009, 93(3):637-645. [10] 周荣, 田橙, 郑智. 原发性高血压左心室不同构型心律失常的比较[J]. 中华心律失常杂志, 2002, 6(2):75. [11] 王变珍, 郭果林. 高血压病发生心律失常的临床观察及研究[J]. 实用心电学杂志, 2007, 16(2):108. [12] Drazner MH. The progression of hypertensive heart disease[J].Circulation, 2011, 123(3):327-334. [13] 杨静, 李立环. 围术期心肌缺血的监测和治疗[J]. 临床麻醉学杂志,2006, 22(9):719-721. [14] Tobias JD, Chrysostomou C. Dexmedetomidine:antiarrhythmic effects in the pediatric cardiac patient[J]. Pediatr Cardiol, 2013, 34(4):779-785. [15] Ji F, Li Z, Nguyen H, et al.Perioperative Dexmedetomidine Improves Outcomes of Cardiac Surgery[J]. Circulation, 2013, 127(15):1576-1584. [16] Roekaerts PM, Prinzen FW, De Lange S. Beneficial effects of dexmedetomidineon ischaemic myocardium of anaesthetized dogs[J]. Br J Anaesth, 1996, 77(3):427-429. [17] Ibacache M, Sanchez G, Pedrozo Z, et al.Dexmedetomidine preconditioning activates pro-survival kinases and attenuates regional ischemia/reperfusion injury in rat heart[J]. Biochimica Biophysica Acta, 2012, 1822(4):537-545. |